Microfluidic Lung-on-Chip for Aerosol Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for testing aerosolized products, such as tobacco, rely heavily on animal testing, which is costly, time-consuming, and raises ethical concerns, while in vitro models lack the complexity of systemic interactions found in vivo, necessitating the development of more predictive and animal-free testing methods.
Innovation Solution
A synthetic organ-on-chip microfluidic device that mimics lung tissue and airways, allowing for the introduction and simulation of aerosols, enabling the evaluation of vapor or aerosol products by replicating specific lung structures and conditions, including temperature and humidity, to simulate human or mammalian respiratory tract interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If in vitro testing methods are used, then animal testing is reduced, but the complexity of systemic interactions is lost
Solution Approach 1:
The patent creates a microfluidic copy of the lung airway structure that replicates the physical and physiological characteristics of real lung tissue. The device includes a microfluidic channel network that mimics the bronchial tree architecture, allowing aerosol particles to interact with lung epithelial cells in a controlled in vitro environment while maintaining biological relevance.
Solution Approach 2:
The patent controls multiple physiological parameters including temperature (37°C), humidity (100% relative humidity), pH (7.4), and oxygen concentration (5% O2) to replicate in vivo lung conditions. These parameter changes transform a simple cell culture into a physiologically relevant model that maintains cell viability and functional responses.
2Reliability
If whole-animal in vivo testing is used, then systemic interactions are captured, but cost and time requirements increase
Solution Approach 1:
The patent segments the complex in vivo system into isolated microfluidic components that can be independently cultured and tested. The lung airway epithelial cells are separated from other organ systems but maintained in a controlled microenvironment that preserves their physiological function, allowing parallel testing of multiple conditions simultaneously.
Solution Approach 2:
The patent transitions from three-dimensional whole-animal testing to a two-dimensional microfluidic platform that maintains physiological relevance through controlled environmental parameters. The microfluidic channel system creates a planar representation of the lung airway that captures particle deposition and cellular responses without requiring systemic biological processes.
3Device complexity
If conventional in vitro cell culture is used, then simplicity is maintained, but aerosol particle interaction complexity is reduced
Solution Approach 1:
The patent applies local quality by creating regions within the microfluidic device that have different characteristics - the microfluidic channels provide controlled flow conditions for aerosol delivery, while the cell culture regions provide biological interfaces for particle deposition. Each region is optimized for its specific function while contributing to the overall system performance.
Data Source
Figure 1
AI summary
A synthetic organ includes one or more airways and a first opening in communication with the one or more airways configured to introduce a vapor, aerosol, or other airborne material into the one or more airways; an organ-on-chip microfluidic device having respiratory tract or lung tissue or cells; and one or more mounting positions within the one or more airways configured to accept the organ-on-chip microfluidic device, the mounting position(s) configured to accept the organ-on-chip microfluidic device are at a position relative to the first opening to replicate specific portions of a lung.